Decision Diagnostics Corp. (OTCBB:DECN) Makes New Peaks

When a stock is poised at a two-year peak, it warrants extra attention. For Decision Diagnostics Corp. (OTCBB:DECN), the climb is slowing down as the ticker added just around 10% on Wednesday, to stand at 72 cents on dollar volumes of about $569,000. Nearly a million shares on average were bought up in the past few days.

DECN has a curious mix of the medical and smartphone technology, offering both home-based tests such as blood glucose, and software products that help keep and share medical records. This leaves DECN with the following financials:

• $160 thousand cash

• $3.5 million total current assets

• $4 million total current liabilities

• $377 thousand revenues

• $1,7 million net loss

The past months saw press releases from DECN showing that it would try to enter the market with cheaper blood glucose testing strips, and would challenge directly the leaders in a desirable growth market. But for a stock’s movements, all those developments may be too far out in the future.

DECN has not been formally promoted since March, and Stock Outlaws moved on to other selections a long time ago. Now, the lawsuit against Johnson&Johnson is seen as a hot opportunity for DECN to make itself into a historical name, if it succeeds defending its own glucose strips against the Johnson&Johnson version. If successful, DECN may reap the benefits of a large infrastructure of glucose meter devices, and just offer the strips, without the large costs of developing the products and supply chains.

And the latest news and business potential are leaving the March promotional effect way behind, in price as well as in volumes. It seems like DECN is enjoying true investors’ trust, while still being at a relatively accessible price.

In this, DECN recalls the high potential of Southern ITS Int’l Inc. (OTCMKTS:SITS), a security technology firm that is paradoxically trading at the double-zero level, but making a believable effort to break through the penny level.

Stock Outlaws specializes in companies that are just about to soar- but its promises fell through for TNI Bio Tech, Inc. (OTCMKTS:TNIB). The ticker was around $5 in the May promotion, but slid sharply, to reach 92 cents.

While the medical industry sometimes may offer quick earnings on a revolutionary product, sometimes the patience of investors is tested. So while DECN may be in for some positive news, a correction is not out of the question, especially after such a significant run-up.